Clinical Trials for Women's Health Brands: A Practical Guide

Women's health is the fastest-growing category in consumer wellness, and it is also the category most often called out for thin or borrowed evidence. Buyers in fertility, menstrual care, perimenopause, menopause, hormonal balance, and longevity are sophisticated. They read the ingredient deck, they read the studies, and they notice when a claim is built on a small mechanism trial rather than a study run on women like them. This guide is a practical playbook for women's health brands that want clinical evidence with the rigor retailers and customers now expect. Why women-specific studies matter Most foundational research in supplements and wellness was historically conducted on majority-male cohorts. For a women's health product, generic ingredient studies usually do not translate cleanly into a defensible marketing claim. Hormone fluctuations across the menstrual cycle, life-stage transitions like perimenopause and menopause, and pregnancy-related contraindications all change how a product needs to be tested. A women-specific study lets you make claims about the actual buyer: "Reduced hot flash frequency by 38% in perimenopausal women over 8 weeks" lands very differently than "clinically studied ingredient." Validated instruments to know Menopause Rating Scale (MRS) and Greene Climacteric Scale for menopausal symptom severity. Female Sexual Function Index (FSFI) for libido and intimacy claims. Premenstrual Symptoms Screening Tool (PSST) for PMS and PMDD-adjacent claims. Pittsburgh Sleep Quality Index (PSQI) for sleep claims tied to hormonal disruption. Hormone panels: estradiol, progesterone, FSH, LH, DHEA-S, testosterone, and thyroid markers depending on the indication. Using validated instruments is what separates a marketing-friendly perception study from a defensible clinical study. The IRB will expect them, and so will any retailer review board worth pitching. Recruitment and eligibility The single most common mistake in women's health studies is loose inclusion criteria. "Women aged 35–65" is not a study population. "Pre-menopausal women aged 35–49 with self-reported PMS in at least 2 of the prior 3 cycles" is. Tight inclusion criteria mean smaller variance, smaller sample sizes, and stronger effect detection. Plan recruitment around life stage: cycle-tracking participants, perimenopausal participants (often defined by FSH and cycle irregularity), surgically vs. naturally menopausal, post-menopausal > 12 months, and pregnancy/breastfeeding exclusions where required. FTC, FDA, and structure-function claims Most women's health supplements are sold under the dietary supplement framework, which means structure-function claims, not disease claims. "Supports healthy menstrual cycles" is acceptable. "Treats endometriosis" is not. The FTC's 2022 health products guidance also raised the bar on what counts as "competent and reliable scientific evidence," and class-action firms have been particularly active in women's wellness. A well-designed RCT with a validated instrument, IRB approval, and a pre-registered endpoint is now the practical floor for a defensible claim in this category. How Citruslabs runs women's health studies Our women's health and longevity practice has run studies across menopause, fertility support, hormonal balance, PMS, libido, sleep, and biomarker-based longevity protocols. Every study is decentralized where appropriate, IRB-approved, biostatistician-designed, and delivered with claim language reviewed against FTC and FDA structure-function guidance. Bring us your product and the buyer you are trying to convince — we'll design the study.